Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Florian Roitner"'
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Clemens Schmitt, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Christian Fridolin Singer, Florian Roitner, Christopher Hager, Johannes Andel, Michael Hubalek, Michael Knauer, Richard Greil
Publikováno v:
Breast Cancer Research, Vol 23, Iss 1, Pp 1-9 (2021)
Abstract Background About 50% of all primary breast cancers show a low-level expression of HER2 (HER2-low), defined as immunohistochemically 1+ or 2+ and lack of HER2 gene amplification measured by in situ hybridization. This low HER2 expression is a
Externí odkaz:
https://doaj.org/article/455c23fb65a7493d9d187d0827208969
Autor:
Gabriel Rinnerthaler, Simon P. Gampenrieder, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P3-05
Background: Hormone-receptor (HR) status, HER2 Status, de novo metastatic disease, distant recurrence-free interval (DRFI), and visceral disease are known prognostic factors in metastatic breast cancer (MBC). Therefore, in the majority of clinical tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0e32f9a0b2d18076dbbc62f6d3aed29
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
https://doi.org/10.1158/1538-7445.sabcs22-p3-05-49
Autor:
Simon Peter Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marij Balic, Sonja Heibl, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-21
Background: BM are generally associated with poor prognosis and with neurological impairments making BM a major limitation of life expectancy and quality of life in MBC. Real-world data are needed in order to quantify and better characterize this spe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::14f8681a4166c26a9774b3cbe1cec808
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
https://doi.org/10.1158/1538-7445.sabcs21-p1-21-08
Autor:
Gabriel Rinnerthaler, Simon P Gampenrieder, Christoph Tinchon, Andreas Petzer Petzer, Marija Balic, Heibl Sonja, August F Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christophe Hager, Michael Hubalek, Michael Knauer, Christian F Singer, Richard Greil
Publikováno v:
Cancer Research. 82:P1-16
Background: Despite the advances by targeted therapies, particularly in HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC), chemotherapy remains a mainstay of the treatment in all breast cancer subtypes. Response probabil
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4aa41106f53bd0c171b3d45688056552
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
https://doi.org/10.1158/1538-7445.sabcs21-p1-16-03
Autor:
Raphael Preiss, Johannes Thaler, Petra Jilma, Ingrid Pabinger, Eva Mikušková, Peter Quehenberger, Stephan Kudrnovsky-Moser, Florian Roitner, Joachim Rettl, Nazanin Samadi, Paul Knoebl, Cihan Ay
Publikováno v:
Thrombosis Research. 207:126-130
BACKGROUND: Cases of ChAdOx1 nCoV-19 (AstraZeneca) vaccinated patients with thrombocytopenia, elevated D-dimer, and elevated platelet factor 4 (PF4) antibody levels with- and without thrombosis have been reported. No recommendations regarding the dur
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::796a8b9f5d794b11fe912efb5bc21408
https://doi.org/10.1016/j.thromres.2021.09.017
https://doi.org/10.1016/j.thromres.2021.09.017
Autor:
S.P. Gampenrieder, V. Dezentjé, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortés Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruché, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Gonçalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortés, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil, Marija Balic, Sonja Heibl, August Felix Zabernigg, Daniel Egle, Margit Sandholzer, Florian Roitner, Johannes Andel, Petra Pichler, Christopher Hager, Michael Knauer, Michael Hubalek, Claudia Bighin, Michelino De Laurentiis, Sabino De Placido, Fabio Puglisi, Luca Boni, Amelie de Gregorio, Tom Degenhardt, Luigi Formisano, Karin Beelen, Timothy Robinson, Amanda Fitzpatrick, Veronique Dieras, Volkmar Muller, Alessandra Gennari, Sabine Linn, Sofia Braga, Javier Cortes, Carlo Palmieri
Publikováno v:
ESMO open. 8(1)
Funding Information: This project was initiated at the Endeavour Breast Project coordinated by Daiichi Sankyo (special thanks to Christian Opitz and Britta Mazur from Daiichi Sankyo). We thank all participants and the steering committee members of th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6a2cfd454951606b7db15bc6bb3b4b0
https://pubmed.ncbi.nlm.nih.gov/36563519
https://pubmed.ncbi.nlm.nih.gov/36563519
Autor:
Simon P. Gampenrieder, Gabriel Rinnerthaler, Christoph Tinchon, Andreas Petzer, Marija Balic, Sonja Heibl, Margit Sandholzer, August F. Zabernigg, Daniel Egle, Christopher Hager, Petra Pichler, Florian Roitner, Johannes Andel, Kathrin Strasser-Weippl, Michael Knauer, Michael Hubalek, Christian F. Singer, Richard Greil
Publikováno v:
Cancer Research. 83:P4-01
Background: New anti-HER2 drugs such as tucatinib and trastuzumab deruxtecan (T-DXd) have shown to improve survival of HER2+ MBC in clinical phase III trials. To allow a future confirmation of this survival advantage in real world, we evaluated the p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::70a4b8526bec048e7dcf2bc9c4a9d0b4
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27
https://doi.org/10.1158/1538-7445.sabcs22-p4-01-27
Autor:
Margit Sandholzer, August Zabernigg, Florian Roitner, Daniel Egle, Michael Knauer, Richard Greil, Sonja Heibl, Christoph Tinchon, Daniela Voskova, Michael Hubalek, Gabriel Rinnerthaler, Andreas L. Petzer, Christoph Suppan, Johannes Andel, Simon Peter Gampenrieder, Christian F. Singer
Publikováno v:
Cancer Research. 81:PS12-21
Background: International guidelines recommend endocrine-based first-line therapy [ET] in hormone receptor-positive, HER2-negative (HR+/HER2- or luminal) metastatic breast cancer (MBC), nowadays in combination with a CDK4/6 inhibitor. Several real-wo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a76308387e2dd357e188a5db501d998e
https://doi.org/10.1158/1538-7445.sabcs20-ps12-21
https://doi.org/10.1158/1538-7445.sabcs20-ps12-21
Autor:
Michael Knauer, Gabriel Rinnerthaler, Sonja Heibl, Simon P. Gampenrieder, Richard Greil, Johannes Andel, August Zabernigg, Andreas L. Petzer, Christoph Suppan, Margit Sandholzer, Christian F. Singer, Daniel Egle, Daniela Voskova, Christoph Tinchon, Florian Roitner, Michael Hubalek
Publikováno v:
Cancer Research. 81:PS1-41
Background: Metastatic breast cancer (MBC) is generally thought to be a systemic and incurable disease requiring systemic therapy. However, surgical resection of oligometastatic disease might be of benefit similar to other malignant diseases. Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::911e483d132a7adf07af456c23266fc7
https://doi.org/10.1158/1538-7445.sabcs20-ps1-41
https://doi.org/10.1158/1538-7445.sabcs20-ps1-41
Autor:
Florian Roitner
Publikováno v:
Journal für Strafrecht. 9:34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62afd2a7c02e65c770cdb5923ea56a51
https://doi.org/10.33196/jst202201003401
https://doi.org/10.33196/jst202201003401